Theravance Biopharma to Participate in an Upcoming Investor Conference
Theravance Biopharma (NASDAQ: TBPH) has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference. The presentation is scheduled for Wednesday, February 12 at 12:00 pm EST (9:00 am PST/5:00 pm GMT).
Investors and interested parties can access the webcast through the Investors section under Events and Presentations on Theravance.com. The webcast recording will remain available on the company's website for 30 days following the presentation.
Theravance Biopharma (NASDAQ: TBPH) ha annunciato la sua partecipazione alla prossima 35a Conferenza Annuale sulla Salute e le Scienze della Vita Oppenheimer. La presentazione è programmata per mercoledì 12 febbraio alle 12:00 EST (9:00 PST / 17:00 GMT).
Gli investitori e le parti interessate possono accedere alla trasmissione in streaming tramite la sezione Investitori sotto Eventi e Presentazioni su Theravance.com. La registrazione della trasmissione rimarrà disponibile sul sito web dell'azienda per 30 giorni dopo la presentazione.
Theravance Biopharma (NASDAQ: TBPH) ha anunciado su participación en la próxima 35ª Conferencia Anual sobre Salud y Ciencias de la Vida Oppenheimer. La presentación está programada para miércoles 12 de febrero a las 12:00 p.m. EST (9:00 a.m. PST / 5:00 p.m. GMT).
Los inversores y partes interesadas pueden acceder a la transmisión en vivo a través de la sección de Inversores bajo Eventos y Presentaciones en Theravance.com. La grabación de la transmisión estará disponible en el sitio web de la empresa durante 30 días después de la presentación.
Theravance Biopharma (NASDAQ: TBPH)는 다가오는 Oppenheimer 제35회 연례 헬스케어 생명과학 컨퍼런스에 참여할 예정이라고 발표했습니다. 발표는 2월 12일 수요일 오후 12시 EST (오전 9시 PST / 오후 5시 GMT)로 예정되어 있습니다.
투자자 및 관심 있는 분들은 Theravance.com의 이벤트 및 발표 섹션에 있는 투자자 섹션을 통해 웹캐스트에 접속할 수 있습니다. 웹캐스트 녹화는 발표 후 30일 동안 회사 웹사이트에서 제공됩니다.
Theravance Biopharma (NASDAQ: TBPH) a annoncé sa participation à la prochaine 35e Conférence Annuelle sur la Santé et les Sciences de la Vie Oppenheimer. La présentation est prévue pour mercredi 12 février à 12h00 EST (9h00 PST / 17h00 GMT).
Les investisseurs et les parties intéressées peuvent accéder au webinaire via la section Investisseurs sous Événements et Présentations sur Theravance.com. L'enregistrement du webinaire restera disponible sur le site de l'entreprise pendant 30 jours après la présentation.
Theravance Biopharma (NASDAQ: TBPH) hat seine Teilnahme an der bevorstehenden 35. jährlichen Healthcare-Life-Science-Konferenz von Oppenheimer angekündigt. Die Präsentation ist für Mittwoch, den 12. Februar um 12:00 Uhr EST (9:00 Uhr PST / 17:00 Uhr GMT) geplant.
Investoren und interessierte Parteien können über den Bereich Investoren unter Veranstaltungen und Präsentationen auf Theravance.com auf den Webcast zugreifen. Die Aufnahme des Webcasts bleibt 30 Tage nach der Präsentation auf der Unternehmenswebsite verfügbar.
- None.
- None.
Webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. Replay of the webcast will be archived on the Company's website for 30 days.
About Theravance Biopharma
Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational once-daily norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA), has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in MSA patients. The Company is committed to creating/driving shareholder value.
For more information, please visit www.theravance.com.
THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).
YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.
Contact:
investor.relations@theravance.com
650-808-4045
View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-to-participate-in-an-upcoming-investor-conference-302368408.html
SOURCE Theravance Biopharma, Inc.
FAQ
When is Theravance Biopharma (TBPH) presenting at the Oppenheimer Healthcare Conference 2025?
How can investors watch TBPH's Oppenheimer Conference presentation?
How long will TBPH's Oppenheimer Conference presentation replay be available?
What time is TBPH's Oppenheimer presentation in PST and GMT?
